A new sandwich immunoassay for detection of the α-secretase cleaved, soluble amyloid-β protein precursor in cerebrospinal fluid and serum

Journal of Alzheimer's Disease

Volumn 37, Issue 4, 2013, Pages 667-678

  Taverna, Mara ^a,b   Straub, Tobias ^c   Hampel, Harald ^d   Rujescu, Dan ^e,f   Lichtenthaler, Stefan F ^a,b,g  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^g Technische Universität München Munich Cluster for Systems Neurology   (Germany)

Author keywords

Alzheimer's disease; amyloid protein precursor; biomarker; sandwich immunoassay; Secretase

Indexed keywords

ALPHA SECRETASE; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; SANDWICH IMMUNOASSAY;

ALZHEIMER'S DISEASE; AMYLOID-Β PROTEIN PRECURSOR; BIOMARKER; SANDWICH IMMUNOASSAY; Α-SECRETASE;

AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; BIOLOGICAL MARKERS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; REGISTRIES;

EID: 84892765272     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130509     Document Type: Article

References (50)

1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer's disease. Lancet 377, 1019-1031.
2. Selkoe DJ (2004) Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 6, 1054-1061.
3. Blennow K, Zetterberg H, Fagan AM (2012) Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med 2, a006221.
4. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K (2010) Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives. Nat Rev Drug Discov 9, 560-574.
5. Blennow K, Hampel H,Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
6. Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H (2011) Novel abeta isoforms in Alzheimer's disease - their role in diagnosis and treatment. Curr Pharm Des 17, 2594-2602.
7. Lichtenthaler SF, Haass C, Steiner H (2011) Regulated intramembrane proteolysis-lessons from amyloid precursor protein processing. J Neurochem 117, 779-796.
8. Lichtenthaler SF (2011) Alpha-secretase in Alzheimer's disease: Molecular identity, regulation and therapeutic potential. J Neurochem 116, 10-21.
9. Kandalepas PC, Vassar R (2012) Identification and biology of beta-secretase. J Neurochem 120(Suppl 1), 55-61.
10. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, Kremmer E, Rossner S, Lichtenthaler SF (2010) ADAM10 is the physiologically relevant, constitutive alphasecretase of the amyloid precursor protein in primary neurons. EMBO J 29, 3020-3032.
11. Jorissen E, Prox J, Bernreuther C, Weber S, Schwanbeck R, Serneels L, Snellinx A, Craessaerts K, Thathiah A, Tesseur I, Bartsch U,Weskamp G, Blobel CP, Glatzel M, De Strooper B, Saftig P (2010) The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J Neurosci 30, 4833-4844.
12. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U,Kojro E, Prinzen C, Endres K, Hiemke C, Blessing M, Flamez P, Dequenne A, Godaux E, van Leuven F, Fahrenholz F (2004) A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113, 1456-1464.
13. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, CitronM(1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.
14. Edbauer D, Winkler E, Haass C, Steiner H (2002) Presenilin and nicastrin regulate each other and determine amyloid betapeptide production via complex formation. Proc Natl Acad Sci U S A 99, 8666-8671.
15. Edbauer D,Winkler E, Regula JT, Pesold B, Steiner H, Haass C(2003) Reconstitution of gamma-secretase activity. Nat Cell Biol 5, 486-488.
16. Kuhn PH, Koroniak K, Hogl S, Colombo A, Zeitschel U, Willem M,Volbracht C, Schepers U, Imhof A, Hoffmeister A, Haass C, Rossner S, Brase S, Lichtenthaler SF (2012) Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J 31, 3157-3168.
17. Dislich B, Lichtenthaler SF (2012) The membrane-bound aspartyl protease BACE1: Molecular and functional properties in Alzheimer's disease and beyond. Front Physiol 3, 8.
18. Reiss K, Saftig P (2009) The "a disintegrin and metalloprotease" (ADAM) family of sheddases: Physiological and cellular functions. Semin Cell Dev Biol 20, 126-137.
19. Haapasalo A, Kovacs DM (2011) The many substrates of presenilin/gamma- secretase. J Alzheimers Dis 25, 3-28.
20. Zhou L, Brouwers N, Benilova I, Vandersteen A, Mercken M, Van Laere K, Van Damme P, Demedts D, Van Leuven F, Sleegers K, Broersen K, Van Broeckhoven C, Vandenberghe R, De Strooper B (2011) Amyloid precursor protein mutation E682K at the alternative beta-secretase cleavage beta'-site increases Abeta generation. EMBO Mol Med 3, 291-302.
21. Lannfelt L, Basun H, Wahlund LO, Rowe BA, Wagner SL (1995) Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Nat Med 1, 829-832.
22. Fellgiebel A, Kojro E, Muller MJ, Scheurich A, Schmidt LG, Fahrenholz F (2009) CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type. J Geriatr Psychiatry Neurol 22, 3-9.
23. Sennvik K, Fastbom J, Blomberg M, Wahlund LO, Winblad B, Benedikz E (2000) Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 278, 169-172.
24. Olsson A, Hoglund K, Sjogren M, Andreasen N, Minthon L, Lannfelt L, Buerger K, Moller HJ, Hampel H, Davidsson P, Blennow K (2003) Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol 183, 74-80.
25. Selnes P, Blennow K, Zetterberg H, Grambaite R, Rosengren L, Johnsen L, Stenset V, Fladby T (2010) Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Res 7, 10.
26. Gabelle A, Roche S, Geny C, Bennys K, Labauge P, Tholance Y, Quadrio I, Tiers L, Gor B, Chaulet C, Vighetto A, Croisile B, Krolak-Salmon P, Touchon J, Perret-Liaudet A, Lehmann S (2010) Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid. Brain Res 1357, 175-183.
27. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Burger K, Hampel H, Frolich L,Wolf S, Prinz B, Jahn H, Luckhaus C, Perneczky R, Hull M, Schroder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kolsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: A multicenter study. Mol Psychiatry 15, 138-145.
28. Rosen C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, Blennow K, Zetterberg H (2012) Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimer's disease. Neuromolecular Med 14, 65-73.
29. Perneczky R, Tsolakidou A, Arnold A, Diehl-Schmid J, Grimmer T, Forstl H, Kurz A, Alexopoulos P (2011) CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology 77, 35-38.
30. Wu G, Sankaranarayanan S,Wong J, Tugusheva K, Michener MS, Shi X, Cook JJ, Simon AJ, Savage MJ (2012) Characterization of plasma beta-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease. J Neurosci Res 90, 2247-2258.
31. Colciaghi F, Marcello E, Borroni B, Zimmermann M, Caltagirone C, Cattabeni F, Padovani A, Di LucaM(2004) Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 62, 498-501.
32. Klyubin I,Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11, 556-561.
33. Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, Kauppinen S, Delacourte A, De Strooper B (2008) Loss of microRNA cluster miR-29a/b- 1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A 105, 6415-6420.
34. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
35. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 12, 189-198.
36. Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, Heyman A (1994) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 44, 609-614.
37. Schmidt KH, Metzler P (1989) Wortschatztest (WST). Hogrefe, Gottingen.
38. Colombo A, Wang H, Kuhn PH, Page R, Kremmer E, Dempsey PJ, Crawford HC, Lichtenthaler SF (2012) Constitutive alpha- and beta-secretase cleavages of the amyloid precursor protein are partially coupled in neurons, but not in frequently used cell lines. Neurobiol Dis 49C, 137-147.
39. Steiner H, Duff K, Capell A, Romig H, Grim MG, Lincoln S, Hardy J, Yu X, Picciano M, Fechteler K, Citron M, Kopan R, Pesold B, Keck S, Baader M, Tomita T, Iwatsubo T, Baumeister R, Haass C (1999) A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling. J Biol Chem 274, 28669-28673.
40. Lichtenthaler SF, Dominguez DI, Westmeyer GG, Reiss K, Haass C, Saftig P, De Strooper B, Seed B (2003) The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem 278, 48713-48719.
41. Tippmann F, Hundt J, Schneider A, Endres K, Fahrenholz F (2009) Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J 23, 1643-1654.
42. Holthoewer D, Endres K, Schuck F, Hiemke C, Schmitt U, Fahrenholz F (2012) Acitretin, an enhancer of alphasecretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein. Neurodegener Dis 10, 224-228.
43. MayPC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, YenM, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, Citron M, Audia JE (2011) Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci 31, 16507-16516.
44. Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM (2009) CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 73, 1353-1358.
45. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease.EMBO Mol Med 1, 371-380.
46. Portelius E, Hansson SF, Tran AJ, Zetterberg H, Grognet P, Vanmechelen E, Hoglund K, Brinkmalm G, Westman- Brinkmalm A, Nordhoff E, Blennow K, Gobom J (2008) Characterization of tau in cerebrospinal fluid using mass spectrometry. J Proteome Res 7, 2114-2120.
47. Dean RA, Shaw LM (2010) Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment. Clin Chem 56, 7-9.
48. Bibl M, Gallus M, Welge V, Esselmann H, Wolf S, Ruther E,Wiltfang J (2012) Cerebrospinal fluid amyloid-beta 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia. J Neural Transm 119, 805-813.
49. Kim ML, Zhang B, Mills IP, Milla ME, Brunden KR, Lee VM (2008) Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. J Neurosci 28, 12052-12061.
50. Decourt B, Sabbagh MN (2011) BACE1 as a potential biomarker for Alzheimer's disease. J Alzheimers Dis 24(Suppl 2), 53-59.